



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Switzerland; <sup>18</sup>Medical Oncology, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, NY, USA

**Background:** Patients with thoracic malignancies may have increased risk for COVID-19 mortality. This risk may be attributable to age, comorbidities, smoking history, pulmonary disease burden and cancer-directed therapies.

**Methods:** TERAVALT is a global consortium examining outcomes and assessing risk factors associated with mortality of patients with thoracic malignancies and COVID-19 infection.

**Results:** As of July 15, 2020, 1012 patients from 20 countries have been entered; median age was 68 with 58 % male, 80% current/former smokers, most common comorbidities of HTN (49%) & COPD (26%); 82% NSCLC, 68 % patients with stage IV disease at COVID diagnosis, 65% on treatment (38% chemotherapy, 26% immune checkpoint inhibitor (ICI), 16 % targeted tyrosine kinase inhibitor (TKI). Of these, 72% were hospitalized; 56% of patients developed complications, most frequently pneumonia (40%) and 47% who did not have prior oxygen therapy required it. 32% of patients died during their COVID-19 infection. Only 33 % of patients continued their oncology treatment after infection. Patients presenting with pneumonia (OR 2.7 2-3.5), consolidation (OR 2 CI 1,5-2,8), bilateral lung abnormalities (OR 2,8 CI 2-3,9) and pleural effusion (OR 2,7 CI 1,8-4) were at increased risk of mortality. In multivariate analysis age  $\geq 65$  (OR 1,53 CI 1,11-2,1), active smoking (OR 2 CI 1,3-3), higher stage of cancer (OR 1,9 CI 1,3-2,7), ECOG PS  $\geq 2$  (OR 3,7 CI 2,7-5), steroids prior to COVID diagnosis (OR 1,8 CI 1,2-2,7), were associated with increased risk of death, while chemotherapy and TKI therapy use were not and interestingly patients on immunotherapy appeared to be at decreased risk for mortality (OR 0,6 CI 0,5-0,97).

**Conclusions:** Facing this ongoing global pandemic, TERAVALT is the largest thoracic malignancy database confirming the high risk for COVID-19 mortality in this specific patient group. Physicians need to evaluate the risk of mortality from COVID-19 based on age, smoking status, stage of cancer, performance status, need for steroids and specific therapy in order to determine the appropriateness for cancer therapy and tailor patient care taking into account patients' wishes and status of pandemic in the country.

**Legal entity responsible for the study:** The authors.

**Funding:** Has not received any funding.

**Disclosure:** J. Baena Espinar: Advisory/Consultancy: AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Angelini. F.R. Hirsch: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: BMS; Advisory/Consultancy: Merck; Advisory/Consultancy: Daiichi; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Lilly/Loxo; Advisory/Consultancy: Boehringer-Ingelheim. M. Tiseo: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Advisory/Consultancy: Novartis; Advisory/Consultancy: MSD; Advisory/Consultancy: BMS; Advisory/Consultancy: Takeda. E. Felip: Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: AbbVie; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: AstraZeneca; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Blue Print Medicines; Advisory/Consultancy, Advisory role or speaker's bureau: Boehringer Ingelheim; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Bristol-Myers Squibb; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: GSK; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Guardant Health; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Medscape; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Merck KGaA; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Merck Sharp and Dohme; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: prIME Oncology; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Springer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Takeda; Advisory/Consultancy, Advisory role or Speaker's bureau: Touchime; Research grant/Funding (self), Research Funding: Fundacion Merck Salud; Research grant/Funding (institution), Research Funding: Grant for Oncology Innovation; Full/Part-time employment, Board (Independent Member: Grifols Boards. H.A. Wakelee: Research grant/Funding (institution), Clinical Research grant: Gilead; Honoraria (self), Advisory/Consultancy, advisor or consultant honoraria: AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution), advisor or consultant, research: Xcovery; Advisory/Consultancy, advisor or consultant: Jassen; Advisory/Consultancy, advisor or consultant: Daiichi Sankyo, INC; Advisory/Consultancy, advisor or consultant: Helsinn; Advisory/Consultancy, advisor or consultant: Mirati; Advisory/Consultancy, advisor or consultant (not: Takeda; Advisory/Consultancy, advisor or consultant (not: Cellworks; Advisory/Consultancy, Research grant/Funding (institution), advisor or consultant (not: Genentech/Roche; Advisory/Consultancy, Research grant/Funding (institution), advisor or consultant (not: Merck; Travel/Accommodation/Expenses, CME presentation (travel funding): Clinical care options oncology, LLC; Travel/Accommodation/Expenses, CME presentation (travel funding): Fishawack facilitate LTD; Travel/Accommodation/Expenses, CME presentation (travel funding): Medscape; Travel/Accommodation/Expenses, CME presentation (travel funding): Onclive/intellisphere LLC; Travel/Accommodation/Expenses, CME presentation (travel funding): Philips Gillmore Oncology 2018; Travel/Accommodation/Expenses, CME presentation (travel funding): Physician education resource, LLC/MJH; Travel/Accommodation/Expenses, CME presentation (travel funding): Potomac center for medical education; Travel/Accommodation/Expenses, CME presentation (travel funding): Prime Oncology LLC (2018); Travel/Accommodation/Expenses, CME presentation (travel funding): Primo (2018); Travel/Accommodation/Expenses, CME presentation (travel funding): Research to practice; Travel/Accommodation/Expenses, CME presentation (travel funding): UpToDate; Travel/Accommodation/Expenses, CME presentation (travel funding): WebMDHealth; Honoraria (self), Research grant/Funding (institution), honoraria, research funding to: Novartis; Travel/Accommodation/Expenses, International professional society: RGCON-Japanese lung cancer conference; Travel/Accommodation/Expenses, International professional society: JKCS - Japanese lung cancer society; Travel/Accommodation/Expenses, International professional society: KSMO - Korean society of medical oncology; Full/Part-time employment, professor of medicine: Stanford university; Travel/Accommodation/Expenses, Scientific advisory committee - travel: ITMIG; Research grant/Funding (institution), research funding to institution: ACEA biosciences. M.C.

Garassino: Honoraria (self): Boehringer Ingelheim; Honoraria (self), Local PI, Enrollment in clinical Trials in: Otsuka Pharma; Honoraria (self), Research grant/Funding (institution), PI, Enrollment and Steering: AstraZeneca; Honoraria (self), Research grant/Funding (institution), PI, Enrollment in clinical Trials in: Novartis; Honoraria (self), Research grant/Funding (institution), PI, Enrollment in clinical Trials in: BMS; Honoraria (self), Research grant/Funding (institution), PI, Enrollment in clinical Trials in: Roche; Honoraria (self), Research grant/Funding (institution), PI, MISP in Thimic malignancies: Pfizer; Honoraria (self), Research grant/Funding (institution), PI, Enrollment in clinical Trials in: Celgene; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Inivata; Research grant/Funding (self): Takeda; Honoraria (self), PI, Enrollment in clinical Trials Thimic: Tiziana Sciences; Honoraria (self), PI, Enrollment in clinical Trials in: Clovis; Honoraria (self), PI, Enrollment in clinical Trials in: Merck Serono; Honoraria (self), Research grant/Funding (self), PI, Enrollment in clinical Trials in: Bayer; Honoraria (self), Research grant/Funding (institution), PI, Enrollment in clinical Trials in: MSD; Honoraria (self), Local PI, Enrollment and Steering: GlaxoSmithKline S.p.A.; Research grant/Funding (institution): Sanofi-Aventis; Honoraria (self), PI, Enrollment in clinical Trials: Spectrum Pharmaceuticals; Honoraria (self), PI, Enrollment in clinical Trials: Blueprint Medicine; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Daiichi Sankyo; Honoraria (self), PI, MISP in Thimic malignancies: Eli Lilly. S. Peters: Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: AbbVie; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Amgen; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: AstraZeneca; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Bayer; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Biocartis; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Boehringer-Ingelheim; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Clovis; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Debiopharm; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Eli Lilly; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: F. Hoffmann-La Roche; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Foundation Medicine; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Illumina; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Janssen; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Merck Sharp and Dohme; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Merck Serono; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Merrimack; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Novartis; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Pharma Mar; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Pfizer; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Regeneron; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Sanofi; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Seattle Genetics and Takeda; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: AstraZeneca; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: Boehringer-Ingelheim; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: Bristol-Myers Squibb; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: Eli Lilly; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: F. Hoffmann-La Roche; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: Merck Sharp and Dohme. L. Horn: Advisory/Consultancy, Consulting: AstraZeneca; Advisory/Consultancy, Consulting: Genentech-Roche; Advisory/Consultancy, Consulting: Incyte; Advisory/Consultancy, Consulting: Merck; Advisory/Consultancy, Consulting: Pfizer; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses, Consulting and travel to meeting: Xcovery; Advisory/Consultancy, Consulting: EMD Serono; Advisory/Consultancy, Consulting: Tesaro; Advisory/Consultancy, Consulting: AbbVie; Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self), Travel/Accommodation/Expenses, Honorarium: BMS; Honoraria (self), Honorarium: Medscape; Honoraria (self), Honorarium: PER; Honoraria (self), Honorarium: Research to Practice; Honoraria (self), Honorarium: OnLive; Advisory/Consultancy, Consulting: Amgen; Advisory/Consultancy, Consulting: Bayer. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2020.08.2316>

LBA76\_PR

Expected medium and long term impact of the COVID-19 outbreak in oncology

G. Jerusalem<sup>1</sup>, C.E. Onesti<sup>2</sup>, D.G. Generali<sup>3</sup>, N. Harbeck<sup>4</sup>, H. Wildiers<sup>5</sup>, G. Curigliano<sup>6</sup>, M. Campone<sup>7</sup>, V. Tjan-Heijnen<sup>8</sup>, M. Martin<sup>9</sup>, M. Cristofanilli<sup>10</sup>, L. Pusztai<sup>11</sup>, R. Bartsch<sup>12</sup>, M. Peeters<sup>13</sup>, G. Berchem<sup>14</sup>, M. Tagliamento<sup>15</sup>, J. Cortés<sup>16</sup>, T. Ruhstaller<sup>17</sup>, E.M. Ciruelos<sup>18</sup>, S. Rottey<sup>19</sup>, H.S. Rugo<sup>20</sup>

<sup>1</sup>Medical Oncology, CHU Sart Tilman Liège and University of Liège, Liège, Belgium; <sup>2</sup>Medical Oncology, CHU Sart Tilman Liege and Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium; <sup>3</sup>UO Patologia Mammaria e Ricerca Trasazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, Cremona, Italy; <sup>4</sup>Breast Cancer, Dept. OB&GYN and CCLMU, Ludwig Maximilians University Hospital, Munich, Germany; <sup>5</sup>Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; <sup>6</sup>Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS and University of Milan, Milan, Italy; <sup>7</sup>Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France; <sup>8</sup>Medical Oncology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands; <sup>9</sup>Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense, Madrid, Spain; <sup>10</sup>Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; <sup>11</sup>Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA; <sup>12</sup>Department of Medicine 1, Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; <sup>13</sup>Oncology Department, University Hospital Antwerp (UZA), Edegem, Belgium; <sup>14</sup>Hemato-Oncology Department, Centre Hospitalier de Luxembourg, Luxembourg; <sup>15</sup>Oncology Department, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy; <sup>16</sup>Oncology Department, IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; <sup>17</sup>Med. Oncology, Breast Center of Eastern Switzerland, St. Gallen, Switzerland; <sup>18</sup>Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain; <sup>19</sup>Department of Medical Oncology, UZ Gent, Gent, Belgium; <sup>20</sup>Breast Care Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

**Background:** The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide.

**Methods:** A 95 items survey was distributed worldwide by 20 oncologists from 10 of the most affected countries in order to evaluate the impact on organization of oncological care.

**Results:** 109 representatives from oncology centers in 18 countries (62.4% academic hospitals) filled out the survey (June 17 – July 14, 2020). A swab or gargle test is systematically performed before day care unit or overnight stay admissions in 27.5% and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing (77.1%) of infected patients was organized in many centers. Treatment modalities mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in 32.1% of centers, and 64.2% of participants agree that under-treatment is a major concern. At the pandemic peak, teleconsultations were performed for follow-up (94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy (57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that they will continue to use telemedicine. Most participants reported more frequent use of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree that virtual meetings are an acceptable alternative to live international meetings. Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4% had an increased scientific activity. Only 18% of participants estimate that their well-being will not recover to previous levels by the end of the year; 63% indicate easily accessible psychological support for caregivers, but only 10% used or planned to use it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers. Major study protocol violations/deviations were observed in 27.5% and significant reductions of clinical trial activities are expected by 37% of centers this year.

**Conclusions:** COVID-19 has a major impact on organization of patient care, well-being of caregivers, continued medical education and clinical trial activities in oncology.

**Legal entity responsible for the study:** The authors.

**Funding:** Fondation Léon Fredericq.

**Disclosure:** G. Jerusalem: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: AbbVie; Travel/Accommodation/Expenses: MedImmune; Travel/Accommodation/Expenses: Merck KGaA. G. Curigliano: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Speaker Bureau/Expert testimony, Writing engagement: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy, Speaker Bureau/Expert testimony: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celltrion; Leadership role, Scientific Affairs Group: Ellipsis; Speaker Bureau/Expert testimony, Writing engagement: BMS; Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan. M. Campone: Honoraria (self), Advisory/Consultancy: GT1; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: Pierre-Favre; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Servier; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy: Accord; Honoraria (institution), Advisory/Consultancy: Pfizer; Speaker Bureau/Expert testimony: Lilly. M. Martin: Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Puma; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Amgen; Advisory/Consultancy: Taiho Oncology; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: PharmaMar; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Pfizer. M. Cristofanilli: Advisory/Consultancy: CytoDyn; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy: G1 Therapeutics; Advisory/Consultancy: Sermonix; Advisory/Consultancy: Genentech. L. Pusztai: Honoraria (self), Research grant/Funding (institution), Clinical trial support: Merck; Honoraria (self), Research grant/Funding (institution), Clinical trial support: AstraZeneca; Honoraria (self), Research grant/Funding (institution), Clinical trial support: Seattle Genetics; Honoraria (self): Novartis; Honoraria (self), Research grant/Funding (institution), Clinical trial support: Roche Genentech; Honoraria (self): Eisai; Honoraria (self): Daiichi; Honoraria (self): Syndax; Honoraria (self): Immunomedics. R. Bartsch: Advisory/Consultancy: Accord; Honoraria (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Daiichi; Advisory/Consultancy, Travel/Accommodation/Expenses: Eli-Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Puma; Advisory/Consultancy: Pierre-Favre; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Eisai. M. Tagliamento: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Amgen. J. Cortés: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Celgene; Advisory/Consultancy: Cellectia; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biothera Pharmaceutical; Advisory/Consultancy: Merus; Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Erytech; Advisory/Consultancy: Athenex + Polyphor; Advisory/Consultancy, Shareholder/Stockholder/Stock options: MedSIR; Honoraria (self), Advisory/Consultancy: Lilly; Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp Dome; Advisory/Consultancy: GSK; Advisory/Consultancy: Leuko; Advisory/Consultancy: Bioasis; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: Eisai; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Samsung Bioepis; Research grant/Funding (institution): Ariad Pharmaceuticals; Research grant/Funding (institution): Baxalta GMBH/Servier Affaires; Research grant/Funding

(institution): Bayer Healthcare; Research grant/Funding (institution): F. Hoffmann-La Roche; Research grant/Funding (institution): Guardanthe Health; Research grant/Funding (institution): Piqu Therapeutics; Research grant/Funding (institution): Puma C; Research grant/Funding (institution): Queen Mary University of London. E.M. Ciruelos: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer. H.S. Rugo: Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly; Research grant/Funding (institution), Travel/Accommodation/Expenses: MacroGenics; Research grant/Funding (institution): Merck; Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Obi Pharma; Research grant/Funding (institution): Odonate Therapeutics; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Daiichi-Sankyo; Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Samsung; Advisory/Consultancy: Celltrion; Travel/Accommodation/Expenses: Mylan; Travel/Accommodation/Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2020.08.2317>

### LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study

A. Marra<sup>1</sup>, D.G. Generali<sup>2</sup>, P. Zagami<sup>3</sup>, S. Gandini<sup>3</sup>, V. Cervoni<sup>4</sup>, S. Venturini<sup>5</sup>, S. Morganti<sup>1</sup>, R. Passerini<sup>6</sup>, R. Orecchia<sup>7</sup>, G. Curigliano<sup>1</sup>

<sup>1</sup>Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative, Istituto Europeo di Oncologia IRCCS, Università di Milano, Milan, Italy; <sup>2</sup>UO Patologia Mammaria e Ricerca Trasazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, Cremona, Italy; <sup>3</sup>Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy; <sup>4</sup>UO Patologia Mammaria e Ricerca Trasazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, Cremona, Italy; <sup>5</sup>Dipartimento di Management, Università di Torino, Turin, Italy; <sup>6</sup>Division of Laboratory Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy; <sup>7</sup>Scientific Direction, Istituto Europeo di Oncologia IRCCS, Milan, Italy

**Background:** Poor outcomes for patients with cancer and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19) have been reported so far. Although anti-SARS-CoV-2 IgG response is usually detectable within three weeks after infection, limited information on the seroconversion rate of patients with cancer infected by SARS-CoV-2 is available.

**Methods:** This is a multicenter, observational, prospective study that included patients and oncology healthcare workers (HCWs) with SARS-CoV-2 infection confirmed by RT-PCR or clinical/radiological suspicious of infection as well as patients with cancer who are considered at high risk for infection. All subjects were tested with the 2019-nCoV IgG/IgM Rapid Test Cassette for the fast detection of IgG and IgM antibodies against SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2 seroconversion rates by qualitative assay in patients with cancer and HCWs with confirmed or clinically suspected COVID-19.

**Results:** At first interim analysis, 166 subjects were enrolled in the study. Cancer patients and HCWs were 61 (36.7%) and 105 (63.3%), respectively. HCWs were younger than patients with cancer (median age 41 vs 62 years;  $P < 0.001$ ). Eighty-six subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on nasopharyngeal swab specimen, while forty-nine (29.5%) had a clinical suspicious of COVID-19 in absence of RT-PCR confirmation. In patients with RT-PCR-confirmed SARS-CoV-2 infection, 62 (83.8%) were IgG-positive. Neither differences in terms of IgG positivity (87.9% vs 80.5%;  $P = 0.39$ ) nor in median time from COVID-19 diagnosis to IgG detection (23.0 vs 28.0 days;  $P = 0.21$ ) were found between patients with cancer and HCWs.

**Conclusions:** Our data show that SARS-CoV-2-specific IgG antibody response is not different between cancer patients and healthy subjects. Qualitative rapid test for antibody detection represents a useful support to RNA RT-PCR testing for the diagnosis of COVID-19 in high-risk populations, including patients with cancer.

**Legal entity responsible for the study:** Istituto Europeo di Oncologia IRCCS.

**Funding:** This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. MEDnoTE srl (Spin-off of University of Trieste) supported the present study by providing the rapid test used for anti-SARS-CoV-2 antibody detection.

**Disclosure:** D.G. Generali: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis, Pfizer, Lilly. G. Curigliano: Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan, Daiichi Sankyo; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly, Pfizer, Merck, Foundation Medicine, Samsung, Celltrion; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics, Nanostring; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Novartis, BMS; Honoraria (self): Ellipsis. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2020.08.2317>